v3.26.1
Revenues (Tables)
 6 Months Ended
Jun. 30, 2026
Revenue from Contract with Customer [Abstract]  
Schedule of Product Revenue The table below presents the Company’s gross and net product revenue ($ in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Product revenue - gross113,675 116,530 215,929 228,863 
Less: Rebates and sales returns(7,924)(7,445)(14,622)(14,128)
Product revenue - net105,751 109,085 201,307 214,735 
Schedule of Disaggregation of Net Revenue
The following table presents the Company’s net revenue by commercial program ($ in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
ZEJULA32,079 41,042 62,046 90,571 
VYVGART / VYVGART Hytrulo23,866 26,497 41,417 44,602 
NUZYRA17,097 14,292 33,359 29,410 
OPTUNE12,202 12,355 24,272 23,718 
QINLOCK9,590 8,536 18,575 17,045 
XACDURO7,957 4,622 16,529 5,739 
AUGTYRO2,213 1,399 4,005 3,025 
KarXT552 — 552 — 
Other (i)195 342 552 625 
Product revenue - net105,751 109,085 201,307 214,735 
(i)Other includes product candidates sold in patient programs prior to commercialization.